Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1956 2
1957 1
1958 2
1959 1
1965 4
1966 1
1968 2
1972 2
1975 1
1976 2
1988 2
1990 1
1993 1
2008 1
2009 3
2010 4
2011 1
2012 3
2013 2
2014 2
2015 1
2016 2
2017 2
2018 2
2019 4
2020 3
2021 5
2022 9
2023 8
2024 12
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer.
Piccinno G, Thompson KN, Manghi P, Ghazi AR, Thomas AM, Blanco-Míguez A, Asnicar F, Mladenovic K, Pinto F, Armanini F, Punčochář M, Piperni E, Heidrich V, Fackelmann G, Ferrero G, Tarallo S, Nguyen LH, Yan Y, Keles NA, Tuna BG, Vymetalkova V, Trompetto M, Liska V, Hucl T, Vodicka P, Bencsiková B, Čarnogurská M, Popovici V, Marmorino F, Cremolini C, Pardini B, Cordero F, Song M, Chan AT, Derosa L, Zitvogel L, Huttenhower C, Naccarati A, Budinska E, Segata N. Piccinno G, et al. Among authors: popovici v. Nat Med. 2025 Jul;31(7):2416-2429. doi: 10.1038/s41591-025-03693-9. Epub 2025 Jun 3. Nat Med. 2025. PMID: 40461820 Free PMC article.
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).
Aroldi F, Elez E, André T, Perkins G, Prenen H, Popovici V, Gallagher P, Houlden J, Collins L, Roberts C, Rolfo C, Di Nicolantonio F, Grayson M, Boyd R, Bettens K, Delfavero J, Coyle V, Lawler M, Khawaja H, Laurent-Puig P, Salto-Tellez M, Maughan TS, Tabernero J, Adams R, Jones R, Hennessy BT, Bardelli A, Peeters M, Middleton MR, Wilson RH, Van Schaeybroeck S; MErCuRIC Trial Consortium. Aroldi F, et al. Among authors: popovici v. BMC Cancer. 2025 Apr 10;25(1):658. doi: 10.1186/s12885-025-14068-1. BMC Cancer. 2025. PMID: 40211189 Free PMC article. Clinical Trial.
Impact of the ONCOBIOME network in cancer microbiome research.
Zitvogel L, Derosa L, Routy B, Loibl S, Heinzerling L, de Vries IJM, Engstrand L; ONCOBIOME Network; Segata N, Kroemer G. Zitvogel L, et al. Nat Med. 2025 Apr;31(4):1085-1098. doi: 10.1038/s41591-025-03608-8. Epub 2025 Apr 11. Nat Med. 2025. PMID: 40217075 Review.
Molecular portraits of colorectal cancer morphological regions.
Budinská E, Hrivňáková M, Ivkovic TC, Madrzyk M, Nenutil R, Bencsiková B, Al Tukmachi D, Ručková M, Zdražilová Dubská L, Slabý O, Feit J, Dragomir MP, Borilova Linhartova P, Tejpar S, Popovici V. Budinská E, et al. Among authors: popovici v. Elife. 2023 Nov 13;12:RP86655. doi: 10.7554/eLife.86655. Elife. 2023. PMID: 37956043 Free PMC article.
Cell death and DNA damage via ROS mechanisms after applied antibiotics and antioxidants doses in prostate hyperplasia primary cell cultures.
Matei E, Ionescu AC, Enciu M, Popovici V, Mitroi AF, Aschie M, Deacu M, Băltățescu GI, Nicolau AA, Roșu MC, Cristian M, Dobrin N, Ștefanov C, Pundiche Butcaru M, Cozaru GC. Matei E, et al. Among authors: popovici v. Medicine (Baltimore). 2024 Sep 13;103(37):e39450. doi: 10.1097/MD.0000000000039450. Medicine (Baltimore). 2024. PMID: 39287312 Free PMC article.
98 results